These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 3899438)

  • 1. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
    Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
    Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of ceftriaxone in hemodialysis].
    Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis.
    Wolter K; Claus M; Wagner K; Fritschka E
    Clin Nephrol; 1994 Dec; 42(6):389-97. PubMed ID: 7882603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
    Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
    Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in erythromycin pharmacokinetics induced by renal failure.
    Kanfer A; Stamatakis G; Torlotin JC; Fredj G; Kenouch S; Méry JP
    Clin Nephrol; 1987 Mar; 27(3):147-50. PubMed ID: 3494560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodialyzability of sertraline.
    Schwenk MH; Verga MA; Wagner JD
    Clin Nephrol; 1995 Aug; 44(2):121-4. PubMed ID: 8529300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis.
    Herrero A; Rius Alarcó F; García Díez JM; Mahiques E; Domingo JV
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):84-7. PubMed ID: 3045024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of moxalactam in anuric children and during hemodialysis.
    Kaplan SL; Berry PL; Mason EO; Kramer WG
    Pediatr Pharmacol (New York); 1983; 3(1):29-36. PubMed ID: 6646877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefamandole in patients undergoing hemodialysis.
    Campillo JA; Lanao JM; Dominguez-Gil A; Tabernero JM; Rubio F
    Int J Clin Pharmacol Biopharm; 1979 Sep; 17(9):416-20. PubMed ID: 500264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
    Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
    Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of hemodialysis on piperacillin pharmacokinetics.
    Heim-Duthoy KL; Halstenson CE; Abraham PA; Matzke GR
    Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):680-4. PubMed ID: 3818147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
    Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
    Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.